Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Chronic kidney disease (CKD) is a major risk factor for atherosclerotic cardiovascular disease.
• Statins (3-hydroxy-3-methylglutaryl coenzyme reductase inhibitors) are widely used to lower low-density lipoprotein cholesterol (LDL-C) and reduce cardiovascular events in the general population.

Purpose of the Study:

• To evaluate the distinct balance of benefits and risks of statin therapy in patients with CKD.
• To explore the potential of statins in reducing CKD progression and acute kidney injury.
• To assess the proven efficacy of statins in reducing cardiovascular events and identify potential adverse effects in CKD patients.

Main Methods:

• Review of recent studies and clinical evidence regarding statin use in CKD patients.
• Analysis of statin's impact on LDL-C levels, CKD progression, and acute kidney injury.
• Examination of cardiovascular event rates and adverse drug effects associated with statins in CKD.

Main Results:

• Statin use may be linked to slower CKD progression and reduced acute kidney injury post-cardiac surgery or contrast exposure.
• The benefit of statins in reducing cardiovascular events in CKD and dialysis patients remains unproven.
• Increased adverse drug effects associated with statins have been observed in CKD patients.

Conclusions:

• Statin therapy presents a complex risk-benefit profile in CKD patients, distinct from the general population.
• Further research is needed to confirm cardiovascular benefits and manage adverse effects of statins in this high-risk group.
• This review addresses the critical considerations for using statins in non-transplanted CKD patients at high cardiovascular risk.